XML 65 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 178,872 $ 131,329
Marketable securities 197,676 510,094
Interest receivable 349 1,035
Accounts receivable 6,013 5,224
Prepaid expenses and other current assets 15,859 11,986
Total current assets 398,769 659,668
Marketable securities, non-current 88,169 50,530
Property and equipment, net 51,523 41,324
Intangible assets 53,760 58,128
Goodwill 39,702 42,798
Operating lease right-of-use assets 73,181 71,045
Other non-current assets 15,319 13,557
Restricted cash 1,500 1,500
Total assets 721,923 938,550
Current liabilities:    
Accounts payable 9,759 12,553
Other accrued liabilities 11,577 18,612
Accrued compensation and employee benefits 20,840 20,738
Deferred revenues 85,711 91,644
Total current liabilities 127,887 143,547
Deferred revenues, non-current 166,776 245,045
Long-term portion of lease liabilities 44,055 38,396
Deferred income tax 6,645 7,185
Other non-current liabilities 1,217 7,011
Total liabilities 346,580 441,184
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.01 par value, 5,000,000 shares authorized, and no shares issued or outstanding 0 0
Common stock, $0.01 par value; 320,000,000 shares authorized, 145,921,530 and 142,063,203 shares issued and outstanding at December 31, 2021 and 2020, respectively 1,459 1,421
Additional paid-in capital 1,334,138 1,269,375
Accumulated deficit (956,267) (777,981)
Accumulated other comprehensive (loss) income (3,987) 5,419
Total Sangamo Therapeutics, Inc. stockholders’ equity 375,343 498,234
Non-controlling interest 0 (868)
Total stockholders’ equity 375,343 497,366
Total liabilities and stockholders’ equity $ 721,923 $ 938,550